The Patent Finder

ACTINIUM-225 and Checkpoint Inhibitor Combination Therapy

Fusion Pharmaceuticals Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,446,401ACTINIUM-225 and Checkpoint Inhibitor Combination Therapy
In force
 · High confidence
Fusion Pharmaceuticals Inc.In forceHigh confidence
Application 17/337,357Radioimmunoconjugates and Checkpoint Inhibitor Combination Therapy
Abandoned
Abandoned May 16, 2026
Fusion Pharmaceuticals Inc.AbandonedAbandoned May 16, 2026
Application 17/819,911Radioimmunoconjugates and Checkpoint Inhibitor Combination Therapy
Abandoned
Abandoned Jun 9, 2025
Fusion Pharmaceuticals Inc.AbandonedAbandoned Jun 9, 2025
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Fusion Pharmaceuticals Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited